Oral yeast carriage in HIV‐infected and non‐infected populations in Rosario, Argentina

The objectives of the present study were: (i) to assess the frequency of oral colonisation by Candida species in HIV‐positive patients and to compare it with a population of HIV‐negative individuals, (ii) to determine the prevalence of C. dubliniensis in both populations and (iii) to determine the susceptibility of C. dubliniensis and other Candida species isolated from HIV‐positive patients to the most commonly used antifungal agents. Oral samples were obtained from 101 HIV‐positive and 108 HIV‐negative subjects. For yeast identification, we used morphology in cornmeal agar, the API 20C Aux, growth at 45 °C, d‐xylose assimilation, morphology in sunflower seed agar and PCR. The frequency of isolation of Candida in HIV‐positive patients was: C. albicans, 60.7%; C. dubliniensis, 20.2%; C. glabrata, 5.6%; C. krusei, 5.6%; C. tropicalis, 4.5%; others, <5%. The frequency of isolation of Candida in HIV‐negative patients was: C. albicans, 73.9%; C. tropicalis, 15.5%; C. dubliniensis, 2.1%; C. glabrata, 2.1%; C. parapsilosis, 2.1%; others, <5%. The oral colonisation by yeast in the HIV‐positive patients was higher than that in the HIV‐negative subjects. The susceptibilities of 42 Candida isolates to three antifungal agents were determined. All isolates of C. dubliniensis were susceptible to fluconazole, although several individuals had been previously treated with this drug. Out of the 42 Candida isolates, 10 presented resistance to fluconazole and 10 to itraconazole. The presence of Candida species, resistant to commonly used antifungal agents, represents a potential risk in immunocompromised patients.

[1]  Maria R R Silva,et al.  Species Distribution and Antifungal Susceptibility Profile of Oral Candida Isolates from HIV-infected Patients in the Antiretroviral Therapy Era , 2006, Mycopathologia.

[2]  S. Córdoba,et al.  Estudio multicéntrico de fungemias por levaduras en la República Argentina , 2005 .

[3]  A. Binolfi,et al.  High prevalence of oral colonization by Candida dubliniensis in HIV-positive patients in Argentina. , 2005, Medical mycology.

[4]  R. Negroni,et al.  [Study of acute vulvovaginitis in sexually active adult women, with special reference to candidosis, in patients of the Francisco J. Muñiz Infectious Diseases Hospital]. , 2004, Revista iberoamericana de micologia.

[5]  M. Mujica,et al.  Prevalencia de Candida albicans y Candida no albicans en diferentes muestras clínicas: Período 1999-2001 , 2004 .

[6]  G. Giusiano,et al.  Yeasts species distribution in Neonatal Intensive Care Units in northeast Argentina , 2004, Mycoses.

[7]  J. Finquelievich,et al.  [Prevalence of Candida albicans and Candida non-albicans in clinical samples during 1999-2001]. , 2004, Revista Argentina de microbiologia.

[8]  H. Gugnani,et al.  Distribution of Candida species in different clinical sources in Delhi, India, and proteinase and phospholipase activity of Candida albicans isolates. , 2003, Revista iberoamericana de micologia.

[9]  D. Coleman,et al.  Differentiation of Candida dubliniensis from Candida albicans on Pal's Agar , 2003, Journal of Clinical Microbiology.

[10]  D. Chattopadhya,et al.  Oropharyngeal carriage of Candida species in HIV‐infected patients in India , 2003, Mycoses.

[11]  G. Quindós,et al.  Candida dubliniensis, a new fungal pathogen , 2002, Journal of basic microbiology.

[12]  M. Cuenca‐Estrella,et al.  Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. , 2002, The Journal of antimicrobial chemotherapy.

[13]  D. Beighton,et al.  Oral yeast carriage in patients with advanced cancer. , 2002, Oral microbiology and immunology.

[14]  G. Pizzo,et al.  Identification of Candida dubliniensis among oral yeast isolates from an Italian population of human immunodeficiency virus-infected (HIV+) subjects. , 2002, Oral microbiology and immunology.

[15]  F. Queiroz-Telles,et al.  Multicenter Brazilian study of oral Candida species isolated from AIDS patients. , 2002, Memorias do Instituto Oswaldo Cruz.

[16]  G. Pizzo,et al.  Candidal carriage in the oral cavity of human immunodeficiency virus-infected subjects. , 2002, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[17]  W. Merz,et al.  Prevalence of yeast among children in Nigeria and the United States. , 2001, Oral microbiology and immunology.

[18]  G. Pizzo,et al.  Fluconazole susceptibility of Italian Candida dubliniensis clinical isolates determined by reference and simplified tests. , 2001, The new microbiologica.

[19]  W. Vivot,et al.  VAGINAL CANDIDACIES: ETIOLOGY AND SENSITIVITY PROFILE TO ANTIFUNGAL AGENT IN CLINICAL USE , 2001 .

[20]  M. Pfaller,et al.  International Surveillance of Bloodstream Infections Due toCandida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program , 2001, Journal of Clinical Microbiology.

[21]  D. Coleman,et al.  Multicenter prospective surveillance of oral Candida dubliniensis among adult Brazilian human immunodeficiency virus-positive and AIDS patients. , 2001, Diagnostic microbiology and infectious disease.

[22]  Sobel,et al.  The Evolution of Candida Species and Fluconazole Susceptibility among Oral and Vaginal Isolates Recovered from Human Immunodeficiency Virus (HIV)-Seropositive and At-Risk HIV-Seronegative Women. , 2001, The Journal of infectious diseases.

[23]  J. Pemán,et al.  In vitro Susceptibility of Candida dubliniensis to Current and New Antifungal Agents , 2000, Chemotherapy.

[24]  C. W. Bailey,et al.  Epidemiology of Oropharyngeal CandidaColonization and Infection in Patients Receiving Radiation for Head and Neck Cancer , 1999, Journal of Clinical Microbiology.

[25]  W. Merz,et al.  Oral Candida dubliniensis as a clinically important species in HIV-seropositive patients in the United States. , 1999, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[26]  D. Ward,et al.  Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. , 1999, AIDS research and human retroviruses.

[27]  S. Donnelly,et al.  Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences. , 1999, Microbiology.

[28]  S. Córdoba,et al.  [Multicenter study on nosocomial candidiasis in the Republic of Argentina]. , 1999, Revista Argentina de microbiologia.

[29]  S. Sanche,et al.  Detection of Candida dubliniensis in Oropharyngeal Samples from Human Immunodeficiency Virus-Infected Patients in North America by Primary CHROMagar Candida Screening and Susceptibility Testing of Isolates , 1998, Journal of Clinical Microbiology.

[30]  H. Goossens,et al.  Cross‐sectional study of oral Candida carriage in a human immunodeficiency virus (HIV)‐seropositive population: predisposing factors, epidemiology and antifungal susceptibility , 1998, Mycoses.

[31]  J. Hernández-Molina,et al.  [In vitro resistance to fluconazole and itraconazole in clinical isolates of Candida spp and Cryptococcus neoformans]. , 1997, Revista iberoamericana de micologia.

[32]  J. Chave,et al.  Asymptomatic oral yeast carriage in HIV-infected patients: frequency and fluconazole susceptibility profile. , 1996, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[33]  D. Coleman,et al.  Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. , 1995, Microbiology.

[34]  D. Wray,et al.  The prevalence of oral candidiasis in HIV-infected individuals and dental attenders in Edinburgh. , 1993, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[35]  W. Powderly,et al.  Amphotericin B-resistant yeast infection in severely immunocompromised patients. , 1988, The American journal of medicine.

[36]  W. Merz,et al.  Incidence of polyene-resistant yeasts recovered from clinical specimens , 1980, Antimicrobial Agents and Chemotherapy.

[37]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .

[38]  C. Vay,et al.  [Prevalence of vaginal candidiasis in pregnant women. Identification of yeasts and susceptibility to antifungal agents]. , 2006, Revista Argentina de microbiologia.

[39]  C. Vay,et al.  Prevalencia de candidiasis vaginal en embarazadas: Identificación de levaduras y sensibilidad a los antifúngicos , 2006 .

[40]  S. Córdoba,et al.  [Multicenter study of fungemia due to yeasts in Argentina]. , 2005, Revista Argentina de microbiologia.

[41]  M. Negroni,et al.  [Candida carriage in the oral mucosa of a student population: adhesiveness of the strains and predisposing factors]. , 2002, Revista Argentina de microbiologia.

[42]  W. Vivot,et al.  [Vaginal candidiasis: etiology and sensitivity profile to antifungal agents in clinical use]. , 2001, Revista Argentina de microbiologia.

[43]  M. Losso,et al.  [Yeast infections: causative agents and their antifungal resistance in hospitalized pediatric patients and HIV-positive adults]. , 1997, Revista Argentina de microbiologia.

[44]  C. Tur,et al.  Resistencia in vitro al fluconazol e itraconazol en aislamientos clínicos de Candida spp y Cryptococcus neo , 1997 .

[45]  D. Sullivan,et al.  Candida Dubliniensis: an Update Forum Micológico , 2022 .